Startek - SRT Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Startek in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRT shares.
View SRT analyst ratings or view top-rated stocks.

1 brokers have issued 12 month price targets for Startek's stock. Their SRT share price forecasts range from $5.50 to $6.00. On average, they predict the company's share price to reach $5.75 in the next year. This suggests a possible upside of 91.7% from the stock's current price.
View analysts price targets for SRT or view top-rated stocks among Wall Street analysts.

Startek's stock was trading at $5.22 at the beginning of 2022. Since then, SRT stock has decreased by 42.5% and is now trading at $3.00.
View the best growth stocks for 2022 here.

Startek saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 91,400 shares, a decline of 50.1% from the August 15th total of 183,000 shares. Based on an average daily trading volume, of 89,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.9% of the shares of the stock are sold short.
View Startek's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our SRT earnings forecast.

Startek, Inc. (NYSE:SRT) issued its quarterly earnings data on Monday, August, 8th. The business services provider reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.07. The business services provider earned $167.64 million during the quarter, compared to analyst estimates of $160.34 million. Startek had a net margin of 1.08% and a trailing twelve-month return on equity of 4.12%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Startek investors own include Amicus Therapeutics (FOLD), KeyCorp (KEY), SentinelOne (S), Vishay Intertechnology (VSH), Huntington Bancshares (HBAN), Kindred Biosciences (KIN), Mitek Systems (MITK), People's United Financial (PBCT), Pfizer (PFE) and Primo Water (PRMW).

Startek trades on the New York Stock Exchange (NYSE) under the ticker symbol "SRT."

Shares of SRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRT stock can currently be purchased for approximately $3.00.

Startek (NYSE:SRT) has a market capitalization of $121.02 million and generates $703.63 million in revenue each year. The business services provider earns $1.50 million in net income (profit) each year or $0.18 on an earnings per share basis.

The company employs 45,000 workers across the globe.

Startek's mailing address is 6200 SOUTH SYRACUSE WAY SUITE 485, GREENWOOD VILLAGE CO, 80111. The official website for the company is www.startek.com. The business services provider can be reached via phone at (303) 262-4500, via email at investor@startek.com, or via fax at 302-655-5049.